U19AI181767
Cooperative Agreement
Overview
Grant Description
The Michigan Infectious Disease Genomics (MIDGE) Center - Project Summary – Overall
The advent of genomic sequencing technologies has revolutionized our understanding of disease transmission, pathogen evolution, drug resistance, and virulence.
Pathogens can quickly adapt to new environments and treatments, making it critical to understand the underlying genetic changes that drive this process.
The proposed Michigan Infectious Disease Genomics (MIDGE) Center will feature four projects, each focused on a group of pathogens, unified by a common theme of identifying pathogen determinants of epidemic success and by a common approach that combines genomic surveillance, functional genomics, and high-throughput phenotyping assays.
Project 1 examines the genomic determinants of epidemic success in SARS-CoV-2, RSV, and influenza viruses.
Here, epidemic success is linked to the virus’s ability to transmit and spread within an immune population through mutations that either increase intrinsic transmissibility or allow for escape from neutralizing antibodies.
Project 2 investigates the impact of genetic background on the emergence and spread of carbapenem-resistant Enterobacterales, where epidemic success is linked not only to drug resistance genes and mutations but also to the genetic background on which they arise.
Project 3 will define genetic and genomic determinants of colonization in Candida auris, an emerging fungal pathogen.
The key to the epidemic success of C. auris appears to be its remarkable ability to adhere to and colonize the skin and the built environment, and this project will leverage whole genome sequencing, microbial GWAS, and functional genomic screens to identify the genetic circuitry for this trait.
Project 4 uses functional genomic approaches to understand the virulence of epidemic strains of Toxoplasma gondii, which are more common in South America and cause a distinct disease from that associated with other globally dispersed lineages.
Genomic surveillance of scat from wild cats will be used to further define the diversity of potentially epidemic, hypervirulent strains in this region.
A technical and data core will support the work of all four projects with staff bioinformaticians and research data analysts as well as investigators with expertise in phylogenetics, high-throughput phenotyping assays, and analysis of complex data sets.
The administrative core will leverage local strengths in training and outreach and provide an infrastructure for regulatory compliance, financial reporting, and data and resource sharing.
Through successful execution of this research plan, the MIDGE Center will develop genomic methods and protocols to study infectious diseases and will advance genomics more broadly in basic and clinical research across viral, bacterial, fungal, and parasitic pathogens.
The advent of genomic sequencing technologies has revolutionized our understanding of disease transmission, pathogen evolution, drug resistance, and virulence.
Pathogens can quickly adapt to new environments and treatments, making it critical to understand the underlying genetic changes that drive this process.
The proposed Michigan Infectious Disease Genomics (MIDGE) Center will feature four projects, each focused on a group of pathogens, unified by a common theme of identifying pathogen determinants of epidemic success and by a common approach that combines genomic surveillance, functional genomics, and high-throughput phenotyping assays.
Project 1 examines the genomic determinants of epidemic success in SARS-CoV-2, RSV, and influenza viruses.
Here, epidemic success is linked to the virus’s ability to transmit and spread within an immune population through mutations that either increase intrinsic transmissibility or allow for escape from neutralizing antibodies.
Project 2 investigates the impact of genetic background on the emergence and spread of carbapenem-resistant Enterobacterales, where epidemic success is linked not only to drug resistance genes and mutations but also to the genetic background on which they arise.
Project 3 will define genetic and genomic determinants of colonization in Candida auris, an emerging fungal pathogen.
The key to the epidemic success of C. auris appears to be its remarkable ability to adhere to and colonize the skin and the built environment, and this project will leverage whole genome sequencing, microbial GWAS, and functional genomic screens to identify the genetic circuitry for this trait.
Project 4 uses functional genomic approaches to understand the virulence of epidemic strains of Toxoplasma gondii, which are more common in South America and cause a distinct disease from that associated with other globally dispersed lineages.
Genomic surveillance of scat from wild cats will be used to further define the diversity of potentially epidemic, hypervirulent strains in this region.
A technical and data core will support the work of all four projects with staff bioinformaticians and research data analysts as well as investigators with expertise in phylogenetics, high-throughput phenotyping assays, and analysis of complex data sets.
The administrative core will leverage local strengths in training and outreach and provide an infrastructure for regulatory compliance, financial reporting, and data and resource sharing.
Through successful execution of this research plan, the MIDGE Center will develop genomic methods and protocols to study infectious diseases and will advance genomics more broadly in basic and clinical research across viral, bacterial, fungal, and parasitic pathogens.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Michigan
United States
Geographic Scope
State-Wide
Regents Of The University Of Michigan was awarded
Genomic Determinants of Infectious Disease Epidemics
Cooperative Agreement U19AI181767
worth $6,233,451
from the National Institute of Allergy and Infectious Diseases in June 2024 with work to be completed primarily in Michigan United States.
The grant
has a duration of 3 years and
was awarded through assistance program 93.855 Allergy and Infectious Diseases Research.
The Cooperative Agreement was awarded through grant opportunity Genomics Centers for Infectious Diseases (U19 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 6/20/24
Period of Performance
6/14/24
Start Date
5/31/27
End Date
Funding Split
$6.2M
Federal Obligation
$0.0
Non-Federal Obligation
$6.2M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for U19AI181767
Additional Detail
Award ID FAIN
U19AI181767
SAI Number
U19AI181767-3459632786
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NM00 NIH NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Funding Office
75NM00 NIH NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Awardee UEI
GNJ7BBP73WE9
Awardee CAGE
03399
Performance District
MI-90
Senators
Debbie Stabenow
Gary Peters
Gary Peters
Modified: 6/20/24